The firm will use the proceeds to advance preclinical studies of its small interfering RNA therapy in KRAS-mutant colorectal and pancreatic cancer.
The firm will use the proceeds to advance BE-101 for hemophilia B through clinical proof-of-concept testing and BE-102 for hypophosphatasia into the clinic.
On the third day, drugmakers provided updates on precision medicines for cancer and Alzheimer's, and Grail talked about the launch of a new version of the Galleri test.
The change in policy at the health system follows the death of a DPD deficient patient and comes during a period of intense competition among Boston hospitals.
The firms will combine Caris' multimodal genomic data with Ontada's community oncology-based real-world data to support cancer drug development.
Despite Leqembi's initial slow sales, the firm's CEO cited areas for the drug's growth and ambitions for an antisense ...
The firm will evaluate its CLDN6- and CD3 T-cell-engaging bispecific antibody in advanced or metastatic ovarian, endometrial, and testicular cancers.
OIG Recommends Changes in FDA Accelerated Approval After Flagging Concerns With Aduhelm, Other Drugs
The OIG recommended that the FDA define factors that would trigger an application's review by an agency council, which the agency disagreed with.
The firm is aiming to break even on its cash flow by 2027 by narrowing its focus on its sarcoma treatments and pipeline candidates with the greatest potential.
The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...
The firm aims to advance two breast cancer therapies in HR-positive, HER2-negative advanced breast cancer this year.
The firm will use the funds to establish a commercial lab and continue advancing its AI- and sequencing-based platform for personalizing cancer treatment.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback